378 related articles for article (PubMed ID: 33757986)
1. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
Wu X; Nelson M; Basu M; Srinivasan P; Lazarski C; Zhang P; Zheng P; Sandler AD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757986
[TBL] [Abstract][Full Text] [Related]
2. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
3. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
4. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
Melaiu O; Mina M; Chierici M; Boldrini R; Jurman G; Romania P; D'Alicandro V; Benedetti MC; Castellano A; Liu T; Furlanello C; Locatelli F; Fruci D
Clin Cancer Res; 2017 Aug; 23(15):4462-4472. PubMed ID: 28270499
[No Abstract] [Full Text] [Related]
6. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma.
Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L
Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803
[TBL] [Abstract][Full Text] [Related]
7. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
8. Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma.
Lee S; Rellinger EJ; Kim KW; Craig BT; Romain CV; Qiao J; Chung DH
Surgery; 2015 Sep; 158(3):819-26. PubMed ID: 26067464
[TBL] [Abstract][Full Text] [Related]
9. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
[TBL] [Abstract][Full Text] [Related]
10. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
11. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
[TBL] [Abstract][Full Text] [Related]
12. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
13. CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma.
Wu X; Srinivasan P; Basu M; Zimmerman T; Li S; Wang Y; Zheng P; Liu Y; Sandler AD
Front Immunol; 2023; 14():1176370. PubMed ID: 37346042
[TBL] [Abstract][Full Text] [Related]
14. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
15. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
16. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts.
Lin LL; Huang CC; Wu CL; Wu MT; Hsu WM; Chuang JH
Lab Invest; 2016 Jul; 96(7):719-30. PubMed ID: 27183205
[TBL] [Abstract][Full Text] [Related]
19. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells.
Zirath H; Frenzel A; Oliynyk G; Segerström L; Westermark UK; Larsson K; Munksgaard Persson M; Hultenby K; Lehtiö J; Einvik C; Påhlman S; Kogner P; Jakobsson PJ; Henriksson MA
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10258-63. PubMed ID: 23733953
[TBL] [Abstract][Full Text] [Related]
20. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
